These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings. Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341 [TBL] [Abstract][Full Text] [Related]
6. [Esmolol in anesthesiology: pharmacology and indications]. Fita G; Gomar C; Rovira I Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078 [TBL] [Abstract][Full Text] [Related]
7. Use of esmolol to control autonomic instability of tetanus. King WW; Cave DR Am J Med; 1991 Oct; 91(4):425-8. PubMed ID: 1683152 [TBL] [Abstract][Full Text] [Related]
8. Carvedilol outclasses the other beta-blockers. Cardiovasc J S Afr; 2001; 12(2):120-1. PubMed ID: 11474696 [No Abstract] [Full Text] [Related]
9. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy. Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552 [TBL] [Abstract][Full Text] [Related]
10. Acute theophylline toxicity and the use of esmolol to reverse cardiovascular instability. Seneff M; Scott J; Friedman B; Smith M Ann Emerg Med; 1990 Jun; 19(6):671-3. PubMed ID: 1971502 [TBL] [Abstract][Full Text] [Related]
11. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life. Covinsky JO Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993 [TBL] [Abstract][Full Text] [Related]
12. A symposium: Bevantolol--a new cardiovascular agent with a unique profile. April 21, 1985, Geneva, Switzerland. Am J Cardiol; 1986 Nov; 58(12):1E-44E. PubMed ID: 2878594 [No Abstract] [Full Text] [Related]
13. Esmolol: a novel ultra-short acting beta-adrenoreceptor blocking agent. Singh BN; Laddu AR Ration Drug Ther; 1986 Aug; 20(8):1-7. PubMed ID: 2882545 [No Abstract] [Full Text] [Related]
14. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Barbier GH; Shettigar UR; Appunn DO Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691 [TBL] [Abstract][Full Text] [Related]
15. [Repercussions of esmolol given in the treatment of postoperative tachycardia on left ventricular function]. Le Bret F; Coriat P; Daas G; Kalfon F; Lasnier H; Arthaud M; Viars P Ann Fr Anesth Reanim; 1989; 8 Suppl():R94. PubMed ID: 2574968 [No Abstract] [Full Text] [Related]
16. Perioperative use of esmolol. Reves JG; Flezzani P Am J Cardiol; 1985 Oct; 56(11):57F-62F. PubMed ID: 2864850 [TBL] [Abstract][Full Text] [Related]
18. Esmolol and the adrenergic response to perioperative stimuli. Murthy VS; Hwang TF; Sandage BW; Laddu AR J Clin Pharmacol; 1986 Mar; 26(S1):A27-A35. PubMed ID: 2870083 [TBL] [Abstract][Full Text] [Related]
19. [Effect of beta receptor blockaders on pulse wave velocity. Studies of the new beta bockader Kö 1366]. Klein K Wien Klin Wochenschr; 1973 Aug; 85(31):536-9. PubMed ID: 4147490 [No Abstract] [Full Text] [Related]
20. Use of esmolol in hypertension after cardiac surgery. Gray RJ; Bateman TM; Czer LS; Conklin C; Matloff JM Am J Cardiol; 1985 Oct; 56(11):49F-56F. PubMed ID: 2864849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]